YALE UNIVERSITY

Three prominent clinical trials testing Paxlovid and monoclonal antibodies for Long COVID failed to show significant health improvements compared to placebo groups.

Northwestern Medicine researchers discovered that Zileuton, an FDA-approved asthma drug, nearly eliminated life-threatening allergic reactions in mice by blocking a previously unknown pathway involving the DPEP1 gene.

Berlin Cures' Phase 2 trial of BC 007 (rovunaptabin) for long COVID failed in November 2024 due to poor patient selection and inadequate outcome measures, despite some participants experiencing dramatic symptom improvements.

Yale researchers developed TMAB3, a specially engineered antibody that successfully delivers RNA therapies to treatment-resistant "cold" tumors, significantly reducing tumor size and extending survival in animal models of pancreatic, brain, and skin cancers.

Yiviva's Phase 2b study demonstrated that YIV-906 plus sorafenib significantly improved median overall survival to 14.3 months versus 7.5 months with sorafenib alone in HBV-positive advanced hepatocellular carcinoma patients.

UCLA Health researchers analyzed 3,500 hospitalized COVID-19 patients and found unvaccinated individuals were 16% more likely to require continuous renal replacement therapy during hospitalization.

Non-human primate studies reveal that increasing Ifenprodil doses from 20 mg to 40-80 mg could achieve 60-80% receptor occupancy, significantly enhancing therapeutic effects for chronic cough treatment.

Brooklyn Health secured $6.5 million in seed funding led by HealthX Ventures to advance its AI-powered clinical trial measurement technology for central nervous system disorders.

A novel cancer vaccine developed at Yale University has demonstrated promising results in canine clinical trials, with multiple dogs showing complete tumor regression after treatment.

Phase II trial results demonstrate that lenacapavir combined with two broadly neutralizing antibodies (teropavimab and zinlirvimab) maintained viral suppression in 96% of participants over 26 weeks, comparable to daily oral regimens.